AVIR Stock — Atea Pharmaceuticals Inc.: Cash, EV, Pipeline

Share price

$5.33

Market cap

$427.5M

Cash

$219.5M

Enterprise value

$208.0M

Balance sheet

Cash	$219.5M
Debt	$0.0M
Net cash	$219.5M
Enterprise value	$208.0M
Basic shares	80.2M shares
Fully diluted shares	111.5M shares
Fully diluted market cap	$594.5M
Cash per share	$2.74

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading AVIR daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Oct 24, 2026	Methadone	Phase 1	Healthy Volunteer Study	—
Jan 12 - Feb 23	Bemnifosbuvir-Ruzasvir	Phase 3	HEPATITIS C VIRUS CHRONIC INFECTION; Hepatitis C, Chronic; Hepatitis C Virus Infection	Q1 2027
Jan 12 - Feb 23	AT-587	Phase 1	Hepatitis E	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

BEM/RZR (bemnifosbuvir + ruzasvir)

Phase 3 · Active Modality: oral antiviral

Target NS5B/NS5A

Partnerships Merck (MSD International GmbH): worldwide exclusive license for ruzasvir (Dec 2021); milestones (incl. $5M on first C-BEYOND patient, Apr 2025) + tiered royalties high single digits to mid-teens

Indications

Hepatitis C virus (HCV) (Phase 3)

Catalysts

— early first quarter 2027
— second quarter 2027

Status note Lead program: fixed-dose combination for HCV. C-BEYOND (US/Canada) reported topline July 2026; C-FORWARD (ex-North America, ~120 sites/17 countries) completed enrollment June 2026; NDA submission targeted second quarter 2027 (pending positive C-FORWARD data).

AT-587

Phase 1 · Active Modality: oral antiviral

Target RdRp

Indications

Hepatitis E virus (HEV) (Phase 1)

Status note Potential first direct-acting antiviral for HEV, focused on chronic HEV in immunocompromised patients. Phase 1 first-in-human trial in healthy volunteers initiated July 2026.

Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Bemnifosbuvir-Ruzasvir
Lead indication	HEPATITIS C VIRUS CHRONIC INFECTION
Lead phase	Phase 3
Active trials	4

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07037277	Phase 3	Active, not recruiting	Sponsor	AVIR	—	HEPATITIS C VIRUS CHRONIC INFECTION; Hepatitis C, Chronic; Hepatitis C Virus Infection	Q1 2027
NCT06868264	Phase 3	Active, not recruiting	Sponsor	AVIR	—	HEPATITIS C VIRUS CHRONIC INFECTION	—
NCT07728487	Phase 1	Recruiting	Sponsor	AVIR	—	Hepatitis E	—
NCT07314346	Phase 1	Recruiting	Sponsor	AVIR	—	Healthy Volunteer Study	—

Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for Atea Pharmaceuticals, Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

AVIR — Atea Pharmaceuticals Inc.